158 related articles for article (PubMed ID: 38785930)
1. Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia.
Basingab FS; Alzahrani RA; Alrofaidi AA; Barefah AS; Hammad RM; Alahdal HM; Alrahimi JS; Zaher KA; Algiraigri AH; El-Daly MM; Alkarim SA; Aldahlawi AM
Biomolecules; 2024 Apr; 14(5):. PubMed ID: 38785930
[TBL] [Abstract][Full Text] [Related]
2. Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma.
Migita K; Sho M; Shimada K; Yasuda S; Yamato I; Takayama T; Matsumoto S; Wakatsuki K; Hotta K; Tanaka T; Ito M; Konishi N; Nakajima Y
Cancer; 2014 Mar; 120(6):808-17. PubMed ID: 24249528
[TBL] [Abstract][Full Text] [Related]
3. RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Lichtenegger FS; Kondla I; Krempasky M; Weber AL; Herold T; Krupka C; Spiekermann K; Schneider S; Büchner T; Berdel WE; Wörmann BJ; Hiddemann W; Subklewe M
Cancer Immunol Immunother; 2015 Dec; 64(12):1505-15. PubMed ID: 26377688
[TBL] [Abstract][Full Text] [Related]
4. Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4.
Aldahlawi A; Basingab F; Alrahimi J; Zaher K; Pushparaj PN; Hassan MA; Al-Sakkaf K
Biomed Rep; 2023 Aug; 19(2):56. PubMed ID: 37560313
[TBL] [Abstract][Full Text] [Related]
5. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma.
Hokuto D; Sho M; Yamato I; Yasuda S; Obara S; Nomi T; Nakajima Y
Eur J Cancer; 2015 Jan; 51(2):157-65. PubMed ID: 25468715
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Han MZ; Wang S; Zhao WB; Ni SL; Yang N; Kong Y; Huang B; Chen AJ; Li XG; Wang J; Wang DH
EBioMedicine; 2019 May; 43():159-170. PubMed ID: 30987862
[TBL] [Abstract][Full Text] [Related]
9. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
[TBL] [Abstract][Full Text] [Related]
10. Significance of Herpesvirus Entry Mediator Expression in Human Colorectal Liver Metastasis.
Sasaki Y; Hokuto D; Inoue T; Nomi T; Yoshikawa T; Matsuo Y; Koyama F; Sho M
Ann Surg Oncol; 2019 Nov; 26(12):3982-3989. PubMed ID: 31313042
[TBL] [Abstract][Full Text] [Related]
11. Interaction between herpesvirus entry mediator and HSV-2 glycoproteins mediates HIV-1 entry of HSV-2-infected epithelial cells.
Hu K; He S; Xiao J; Li M; Luo S; Zhang M; Hu Q
J Gen Virol; 2017 Sep; 98(9):2351-2361. PubMed ID: 28809154
[TBL] [Abstract][Full Text] [Related]
12. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
14. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
15. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
16. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
17. Herpes virus entry mediator, which decreases in HIV infection, can enhance the suppressive activity of regulatory T cell and predict recovery of CD4+T-cells during HAART.
Fu Y; Zhang Z; Jiang Y; Zhang J; Zhao W; Liao C; Shang H
Curr HIV Res; 2015; 13(2):151-9. PubMed ID: 25892413
[TBL] [Abstract][Full Text] [Related]
18. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1
Del Rio ML; de Juan CY; Roncador G; Caleiras E; Álvarez-Esteban R; Pérez-Simón JA; Rodriguez-Barbosa JI
Front Immunol; 2023; 14():1113858. PubMed ID: 37033927
[TBL] [Abstract][Full Text] [Related]
19. Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer.
Tsang JYS; Chan KW; Ni YB; Hlaing T; Hu J; Chan SK; Cheung SY; Tse GM
Ann Surg Oncol; 2017 Dec; 24(13):4042-4050. PubMed ID: 28612127
[TBL] [Abstract][Full Text] [Related]
20. Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.
Park JJ; Anand S; Zhao Y; Matsumura Y; Sakoda Y; Kuramasu A; Strome SE; Chen L; Tamada K
Cancer Immunol Immunother; 2012 Feb; 61(2):203-214. PubMed ID: 21877247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
